Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma

M. Spears; I. Donnelly; L. Jolly; M. Brannigan; K. Ito; C. McSharry; J. Lafferty; R. Chaudhuri; G. Braganza; P. Bareille; L. Sweeney; I. M. Adcock; P. J. Barnes; S. Wood; N. C. Thomson

doi:10.1038/clpt.2009.41

Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma

M. Spears, I. Donnelly, L. Jolly, M. Brannigan, K. Ito, C. McSharry, J. Lafferty, R. Chaudhuri, G. Braganza, P. Bareille, L. Sweeney, I. M. Adcock, P. J. Barnes, S. Wood, N. C. Thomson (Lead / Corresponding author)

Undergraduate Medicine

Research output: Contribution to journal › Article › peer-review

83 Citations (Scopus)

Abstract

Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist would be superior for the clinical treatment of these asthma patients. Forty-six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 νg per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV 1) = 183 ml, P = 0.051; forced expiratory flow between 25 and 75% of the forced vital capacity (FEF 25-75) = 0.24 l/s, P = 0.030) as compared with inhaled beclometasone dipropionate. Further trials using PPAR-γ agonists in steroid-resistant airway disease are indicated.

Original language	English
Pages (from-to)	49-53
Number of pages	5
Journal	Clinical Pharmacology & Therapeutics
Volume	86
Issue number	1
Early online date	8 Apr 2009
DOIs	https://doi.org/10.1038/clpt.2009.41
Publication status	Published - 8 Apr 2009

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1038/clpt.2009.41

Cite this

Spears, M., Donnelly, I., Jolly, L., Brannigan, M., Ito, K., McSharry, C., Lafferty, J., Chaudhuri, R., Braganza, G., Bareille, P., Sweeney, L., Adcock, I. M., Barnes, P. J., Wood, S., & Thomson, N. C. (2009). Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma. Clinical Pharmacology & Therapeutics, 86(1), 49-53. https://doi.org/10.1038/clpt.2009.41

@article{8e3abaa751344a8a89063599d782d9b8,

title = "Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma",

abstract = "Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist would be superior for the clinical treatment of these asthma patients. Forty-six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 νg per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV 1) = 183 ml, P = 0.051; forced expiratory flow between 25 and 75% of the forced vital capacity (FEF 25-75) = 0.24 l/s, P = 0.030) as compared with inhaled beclometasone dipropionate. Further trials using PPAR-γ agonists in steroid-resistant airway disease are indicated.",

author = "M. Spears and I. Donnelly and L. Jolly and M. Brannigan and K. Ito and C. McSharry and J. Lafferty and R. Chaudhuri and G. Braganza and P. Bareille and L. Sweeney and Adcock, {I. M.} and Barnes, {P. J.} and S. Wood and Thomson, {N. C.}",

year = "2009",

month = apr,

day = "8",

doi = "10.1038/clpt.2009.41",

language = "English",

volume = "86",

pages = "49--53",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "American Society for Clinical Pharmacology and Therapeutics",

number = "1",

}

Spears, M, Donnelly, I, Jolly, L, Brannigan, M, Ito, K, McSharry, C, Lafferty, J, Chaudhuri, R, Braganza, G, Bareille, P, Sweeney, L, Adcock, IM, Barnes, PJ, Wood, S & Thomson, NC 2009, 'Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma', Clinical Pharmacology & Therapeutics, vol. 86, no. 1, pp. 49-53. https://doi.org/10.1038/clpt.2009.41

TY - JOUR

T1 - Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma

AU - Spears, M.

AU - Donnelly, I.

AU - Jolly, L.

AU - Brannigan, M.

AU - Ito, K.

AU - McSharry, C.

AU - Lafferty, J.

AU - Chaudhuri, R.

AU - Braganza, G.

AU - Bareille, P.

AU - Sweeney, L.

AU - Adcock, I. M.

AU - Barnes, P. J.

AU - Wood, S.

AU - Thomson, N. C.

PY - 2009/4/8

Y1 - 2009/4/8

N2 - Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist would be superior for the clinical treatment of these asthma patients. Forty-six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 νg per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV 1) = 183 ml, P = 0.051; forced expiratory flow between 25 and 75% of the forced vital capacity (FEF 25-75) = 0.24 l/s, P = 0.030) as compared with inhaled beclometasone dipropionate. Further trials using PPAR-γ agonists in steroid-resistant airway disease are indicated.

AB - Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist would be superior for the clinical treatment of these asthma patients. Forty-six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 νg per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV 1) = 183 ml, P = 0.051; forced expiratory flow between 25 and 75% of the forced vital capacity (FEF 25-75) = 0.24 l/s, P = 0.030) as compared with inhaled beclometasone dipropionate. Further trials using PPAR-γ agonists in steroid-resistant airway disease are indicated.

UR - http://www.scopus.com/inward/record.url?scp=67650617728&partnerID=8YFLogxK

U2 - 10.1038/clpt.2009.41

DO - 10.1038/clpt.2009.41

M3 - Article

C2 - 19357642

AN - SCOPUS:67650617728

SN - 0009-9236

VL - 86

SP - 49

EP - 53

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 1

ER -

Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this